Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Lenalidomide

First Posted Date: 2013-12-23

Last Posted Date: 2018-01-18

Lead Sponsor: Jun Zhang

Target Recruit Count: 7

Registration Number: NCT02018523

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Phase 2

Active, not recruiting

Conditions: Prolymphocytic Leukemia
Contiguous Stage II Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Noncontiguous Stage II Small Lymphocytic Lymphoma
Stage I Small Lymphocytic Lymphoma
Stage III Small Lymphocytic Lymphoma
Stage I Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Small Lymphocytic Lymphoma

Interventions: Biological: MOR00208
Drug: lenalidomide
Other: Correlative Studies

First Posted Date: 2013-12-09

Last Posted Date: 2024-05-17

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 41

Registration Number: NCT02005289

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Velcade
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Melphalan
Drug: Thalidomide
Drug: Diphenhydramine
Drug: Prednisone
Drug: Acetaminophen
Drug: Carfilzomib
Drug: Montelukast
Drug: Lenalidomide

First Posted Date: 2013-12-03

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 240

Registration Number: NCT01998971

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Phase 3

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2013-11-27

Last Posted Date: 2024-10-01

Lead Sponsor: Celgene

Target Recruit Count: 503

Registration Number: NCT01996865

Locations: 🇺🇸
Local Institution - 011, Marietta, Georgia, United States
🇺🇸
Local Institution - 056, Niles, Illinois, United States
🇺🇸
Local Institution - 028, Park Ridge, Illinois, United States

and more 123 locations

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Grade 2 Follicular Lymphoma
Recurrent Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Refractory Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory Small Lymphocytic Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Marginal Zone Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Obinutuzumab

First Posted Date: 2013-11-26

Last Posted Date: 2023-10-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT01995669

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Drug: All-Trans Retinoic Acid (ATRA)

First Posted Date: 2013-11-15

Last Posted Date: 2016-09-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01985477

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Panobinostat
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Bortezomib

First Posted Date: 2013-10-18

Last Posted Date: 2021-09-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01965353

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Relapse
Lymphoma

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2013-10-08

Last Posted Date: 2020-12-17

Lead Sponsor: Institut Curie

Target Recruit Count: 45

Registration Number: NCT01956695

Locations: 🇫🇷
CHU Bretonneau - Centre Henry Kaplan, Tours, Centre, France
🇫🇷
Chu La Timone, Marseille, France
🇫🇷
Hôpital de la Pitié Salpétrière, Paris, Ile De France, France

and more 9 locations

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Phase 1

Terminated

Conditions: Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma
Stage I Multiple Myeloma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: bortezomib
Drug: lenalidomide
Other: laboratory biomarker analysis

First Posted Date: 2013-10-07

Last Posted Date: 2017-02-17

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT01954784

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma
Refractory Lymphoplasmacytic Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Marginal Zone Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Ibrutinib
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2013-10-07

Last Posted Date: 2024-10-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT01955499

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy